本周关注点 公司公告汇总 宁波德业科技股份有限公司将于2025年5月21日召开2024年年度股东大会，会议地点为宁波市北仑区甬 江南路26号研发楼7楼。会议将审议多项议案，包括2024年度董事会工作报告、监事会工作报告、独立 董事述职报告、财务决算报告、年度报告及其摘要、利润分配及资本公积金转增股本方案、使用自有资 金进行现金管理、公司及子公司向银行申请综合授信额度及对外担保额度、开展外汇套期保值业务、董 事薪酬方案、监事薪酬方案等。公司及子公司拟使用最高不超过80亿元的自有资金进行现金管理，并向 银行申请不超过200亿人民币的综合授信额度。此外，公司计划开展不超过15亿美元的外汇套期保值业 务。 业绩披露要点 截至2025年5月9日收盘，德业股份（605117）报收于89.5元，较上周的86.2元上涨3.83%。本周，德业 股份5月8日盘中最高价报90.28元。5月6日盘中最低价报86.1元。德业股份当前最新总市值578.14亿元， 在光伏设备板块市值排名4/62，在两市A股市值排名234/5145。 2024年公司实现营业收入112.06亿元，同比增长49.82%，归属于母公司股东的净利润29.60亿元， ...

中农立华生物科技股份有限公司 二〇二四年年度股东大会 会 议材 料 目 录 议案六：关于确认公司非独立董事、高级管理人员 2024 年度薪酬、津贴的 议案八：关于公司续聘 2025 年度财务报告及内部控制审计机构的议案......8 议案十：关于公司日常关联交易 2024 年度执行情况及 2025 年度预计额度的 议案十三：关于中农立华与供销集团财务有限公司签订《金融服务协议》暨 议案十四：关于中农立华变更经营范围、修订《公司章程》并办理工商变更 议案十五：关于修订《董事会议事规则》等部分公司治理制度的议案......16 议案十六：关于修订《独立董事工作细则》等部分公司治理制度的议案..17 议案十七：关于取消监事会及监事设置、不再施行《监事会议事规则》的议 附件十：日常关联交易 2024 年度执行情况及 2025 年度预计额度的报告..70 附件十二：2024 年度涉 及 财 务 公 司 关 联 交 易 的 存 款 、 贷 款 等 金 融 附件十三：关于中农立华生物科技股份有限公司开展外汇套期保值业务的情 附件十五：关于公司与供销集团财务有限公司签订《金融服务协议》暨关联 二〇二四年年度股东大会 会议议案 ...

Core Viewpoint - Zhejiang Sitaili Pharmaceutical Co., Ltd. is preparing for its shareholder meeting scheduled for May 22, 2025, focusing on maintaining shareholder rights and ensuring orderly proceedings during the meeting [1][2]. Meeting Arrangements - The meeting will be held on May 22, 2025, at 14:30, with online voting available from 9:15 to 11:30 and 13:00 to 15:00 on the same day [3]. - The venue for the meeting is located at No. 9, Fengxi West Road, Modern Industrial Gathering Area, Xianju County, Zhejiang Province [3]. Shareholder Rights and Meeting Conduct - Shareholders have the right to speak, inquire, and vote, but must apply to the meeting's organizing committee to do so [2]. - The voting will be conducted via a named ballot, with each share granting one vote, and any improperly filled ballots will be considered as abstentions [2][3]. Board of Directors and Governance - The fifth board of directors consists of 7 members, including 3 independent directors, and has held 8 meetings during the reporting period to discuss various corporate matters [6]. - The board has focused on maintaining good governance and protecting shareholder interests through active discussions and independent opinions [6]. Financial Performance Overview - The company reported a steady growth in operating performance for 2024, with total assets reaching approximately 6.05 billion yuan, an increase of 9.59% compared to the previous year [15]. - The financial report indicates a decrease in cash and cash equivalents by 14.47% and a decline in accounts receivable by 10.76% [14][15]. Future Outlook - The company anticipates challenges in 2025 due to external factors such as safety and environmental risks, as well as increased competition in the industry [9]. - The board will closely monitor changes in external policies and economic conditions to provide strategic recommendations for sustainable development [9].

Group 1 - The company has decided to postpone the completion date of its fundraising project from December 31, 2024, to December 31, 2025, to ensure the safe and effective use of raised funds and to maintain the interests of the company and its shareholders [7] - In 2024, the company achieved operating revenue of 87,198.12 million, representing a year-on-year increase of 22.27%, while the net profit attributable to shareholders decreased by 19.87% to 6,299.97 million [9] - The decline in net profit despite revenue growth is attributed to the expansion of the company's operational scale and increased expenses under its self-brand development strategy [9] Group 2 - The company conducted foreign exchange trading for hedging purposes on March 19, 2024, and August 5, 2024, but failed to timely fulfill the corresponding review procedures and information disclosure obligations [9] - The company has been advised to actively implement effective measures to reduce costs and increase efficiency in future business development to enhance operational performance [9]

江苏常州 二〇二五年五月二十日 江苏武进不锈股份有限公司（603878） 2024 年年度股东大会会议资料 《关于公司非独立董事（除董事长、副董事长外）薪酬的议案》- 30 - 江苏武进不锈股份有限公司 会议资料 公司登记在册的本公司股东。因故不能亲自出席会议的股东，可以委托授权代理 人参加会议，代理人可以不是本公司股东。 议案八： 江苏武进不锈股份有限公司（603878） 2024 年年度股东大会会议资料 -2- 江苏武进不锈股份有限公司 一、会议时间 ①网络投票系统：上海证券交易所股东大会网络投票系统。 ②网络投票起止时间：自 2025 年 5 月 20 日至 2025 年 5 月 20 日。 ③采用上海证券交易所网络投票系统，通过交易系统投票平台的投票时间为 股东大会召开当日的交易时间段，即 9:15-9:25，9:30-11:30，13:00-15:00；通过 互联网投票平台的投票时间为股东大会召开当日的 9:15-15:00。 二、现场会议地点：江苏省常州市天宁区郑陆镇武澄西路 1 号公司二楼职工 培训室。 三、出席现场会议对象： 四、见证律师：江苏正气浩然律师事务所梁永伟、邹逸韬。 五、现场会议议 ...

Financial Data and Key Metrics Changes - Aflac reported net earnings per diluted share of $0.05, significantly impacted by net investment losses compared to net investment gains in Q1 2024 [5] - Adjusted earnings per diluted share remained unchanged at $1.66 year over year [5][13] - Adjusted return on equity (ROE) was 12.7% excluding foreign currency remeasurement, indicating a solid performance [13] - Adjusted book value per share, excluding foreign currency remeasurement, increased by 2.2% [13] Business Line Data and Key Metrics Changes - Aflac Japan experienced a 12.6% year-over-year sales increase, driven by significant contributions from Sumitas and a 6.3% increase in cancer insurance sales [5][6] - Aflac US saw a 3.5% year-over-year increase in sales, with strong performance in group life, disability, and network dental [8] - Net earned premiums in Aflac Japan declined by 5%, while underlying earned premiums adjusted for deferred profit liability and reinsurance declined by 1.4% [14] - In the US, net earned premiums increased by 1.8%, with persistency rising by 60 basis points year over year to 79.3% [17] Market Data and Key Metrics Changes - Aflac Japan's total benefit ratio was 65.8%, down 120 basis points year over year, while the US total benefit ratio was 47.7%, up 120 basis points year over year [15][18] - Persistency in Japan remained solid at 93.8%, up 40 basis points year over year [16] - The expense ratio in Japan increased to 19.6%, primarily due to higher technology expenses, while the US expense ratio decreased to 37.6% [16][19] Company Strategy and Development Direction - Aflac aims to appeal to younger customers through products like Sumitas, which has been successful in reaching this demographic [6] - The company is focused on maintaining strong premium persistency and driving profitable growth through stronger underwriting discipline [8] - Aflac continues to leverage its strong capital and cash flows while maintaining prudent liquidity and capital management [10] - The company is committed to reinforcing its leading position in the life insurance markets of Japan and the US [12] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the demand for Aflac's products, emphasizing the importance of being a partner in health for policyholders [9] - The company is optimistic about the growth potential in both Japan and the US, with plans to continue capital deployment and maintain a strong dividend track record [11][12] - Management acknowledged the challenges posed by macroeconomic factors but remains committed to long-term capital management strategies [36] Other Important Information - Aflac repurchased $900 million worth of its own stock and paid $317 million in dividends during Q1 2025 [23] - The company ended the quarter with strong capital ratios, including an estimated regulatory ESR above 250% [24] - Aflac Japan's cancer insurance sales are expected to grow, supported by the launch of a new cancer product in March 2025 [52] Q&A Session Summary Question: Why did the ESR ratio decline in Q1? - Management explained that the decline was due to the strengthening yen, partially offset by higher Japan interest rates and significant dividends flowing from Aflac Japan to Aflac Inc [32] Question: How should capital planning be approached given recent macro changes? - Management stated that capital management is designed with a long-term view, and they do not plan to change their approach significantly despite recent volatility [36] Question: What are the expectations for the new cancer product sales? - Management expressed confidence in the new cancer product's growth, anticipating continued sales increases throughout 2025 [52] Question: How is the competitive landscape for medical insurance in Japan? - Management acknowledged increased competition but emphasized Aflac's pioneering position and unique services that provide a competitive advantage [56] Question: How does the company view the impact of the yen on its operations? - Management noted that while a strengthening yen introduces volatility, it also leads to higher future dividends in dollar terms from Aflac Japan, which offsets some negative impacts [95]

登录新浪财经APP 搜索【信披】查看更多考评等级 本年度公司现金分红总额53,812,057.90元；本年度以现金为对价，采用集中竞价方式已实施的股份回购 金额75,864,030.95元，现金分红和回购金额合计129,676,088.85元，占本年度归属于上市公司股东净利润 的比例136.39%。其中，以现金为对价，采用要约方式、集中竞价方式回购股份并注销的回购（以下简 称回购并注销）金额0元，现金分红和回购并注销金额合计53,812,057.90元，占本年度归属于上市公司 股东净利润的比例56.60%。 如在本公告披露之日起至实施权益分派股权登记日期间，因可转债转股/回购股份/股权激励授予股份回 购注销/重大资产重组股份回购注销等致使公司总股本发生变动的，公司拟维持每股分配比例不变，相 应调整分配总额。如后续总股本发生变化，将另行公告具体调整情况。 本次利润分配方案尚需提交股东大会审议。 （二）是否可能触及其他风险警示情形 公司上市已满三个完整会计年度，本年度净利润为正值且母公司报表年度末未分配利润为正值，公司不 触及其他风险警示情形，具体如下： ■ 二、公司履行的决策程序 （一）董事会会议的召开、审议和 ...

2025年04月29日，英飞特2024年度业绩说明会在全景网顺利举行。出席本次业绩说明会的人员有董事、 总经理黄美兰、副总经理、董事会秘书贾佩贤、独立董事竺素娥、副总经理、财务负责人丁丽君。 根据全景数据后台统计，在今天的交流过程中，来自全国多个省、市地区的投资者共向上市公司提问21 个，公司嘉宾共回答问题21个，答复率100.00%，充分实现了上市公司与投资者的良好互动。 以下为业绩说明会问答实录： 1、问：在吗 回答：您好，我在，谢谢您的关注 2、问：？？ 回答：您好！今天公司参与交流的嘉宾有公司董事、总经理黄美兰女士、公司独立董事竺素娥教授，公 司副总经理、财务负责人丁丽君女士，公司副总经理、董事会秘书贾佩贤女士。欢迎广大投资者参与互 动、交流。 3、问：在？ 回答：您好，我在的! 感谢您的关注。 4、问：路演没有音视频吗 回答：您好！本次业绩说明会为线上文字交流，没有设置音视频。欢迎您以文字方式提问，谢谢！ 回答：感谢您的关注！如您指2025年一季度的扣非净利润较上年同期下降，是因为2025年一季度确认的 投资基金公允价值变动收益较上年同期增加所致。 7、问：定增计划中有一致性协议嘛 5、问：路演没有 ...

Core Viewpoint - The company has approved a proposal to engage in foreign exchange hedging activities to mitigate risks associated with currency fluctuations as its overseas business grows [1][2]. Group 1: Foreign Exchange Hedging Activities - The company plans to conduct foreign exchange hedging activities, including but not limited to forward foreign exchange contracts, foreign exchange swaps, foreign exchange options, and other foreign exchange derivatives, with a maximum contract amount of up to 10 million USD or equivalent foreign currency [1]. - The authorization for these activities is valid for 12 months from the date of the board's approval, allowing for the funds to be used in a rolling manner within the specified limit [1]. - The board has authorized the general manager to approve daily foreign exchange hedging plans and sign related contracts, with the finance department responsible for the operation and management of these activities [1]. Group 2: Risk Management and Internal Controls - The foreign exchange hedging activities will primarily involve standard forward foreign exchange products and foreign exchange swaps, limited to the main settlement currencies used in the company's operations [2]. - The maximum delivery period for these hedging activities is generally not to exceed 12 months, and the funding for these activities will come from the company's own funds [2]. - The company has implemented strict internal review and risk control measures, including managing accounts receivable actively to prevent delays in delivery for forward foreign exchange contracts [2]. Group 3: Board Approval - The proposal was approved by the company's third board meeting with 7 votes in favor, 0 against, and 0 abstentions, and does not require submission to the shareholders' meeting for further approval [2]. - Relevant documents include the resolution of the third board meeting and the decision from the first special meeting of independent directors in 2025 [2].

登录新浪财经APP 搜索【信披】查看更多考评等级 公司代码：603639 公司简称：海利尔 第一节 重要提示 1、 本年度报告摘要来自年度报告全文，为全面了解本公司的经营成果、财务状况及未来发展规划，投 资者应当到http://www.sse.com.cn网站仔细阅读年度报告全文。 2、 本公司董事会、监事会及董事、监事、高级管理人员保证年度报告内容的真实性、准确性、完整 性，不存在虚假记载、误导性陈述或重大遗漏，并承担个别和连带的法律责任。 3、 公司全体董事出席董事会会议。 2024年公司主要原药产品行情 4、 中兴华会计师事务所（特殊普通合伙）为本公司出具了标准无保留意见的审计报告。 5、 董事会决议通过的本报告期利润分配预案或公积金转增股本预案 经2025年4月28日第五届董事会第八次会议审议通过，公司2024年度利润分配的预案为：以权益分派实 施时股权登记日的总股本为基数，向全体股东每10股派发现金红利5元（含税），公司剩余未分配利润 全额结转下一年度。本预案尚需经股东大会审议。 第二节 公司基本情况 1、 公司简介 2、 报告期公司主要业务简介 农药是农业生产中不可缺少的生产资料，需求相对刚性。长 ...